Context.—

A variety of uncommon malignant endometrial tumors can be challenging to diagnose because of overlapping morphology with more common entities. In some cases, immunohistochemical stains and/or molecular testing allow for more definitive diagnosis or prognostication.

Objective.—

To review classic morphologic features of uncommon endometrial tumors, pathologic features of these tumors and their mimics, and the evidence for use of immunohistochemistry and molecular testing in the diagnosis of these tumors.

Data Sources.—

University of Michigan (Ann Arbor) cases and review of pertinent literature about each entity.

Conclusions.—

Although each of these uncommon endometrial tumors has morphologic mimics, key histologic features, immunohistochemical stains, and molecular testing allow for accurate classification.

Although endometrial carcinoma is a common gynecologic malignancy,1  there is suboptimal interobserver reproducibility in the diagnosis of high-grade endometrial cancers (ECs).2–5  Historically, risk has been determined based on age, stage, histologic subtype, tumor grade, and presence of lymphovascular space invasion.6–8  However, some tumors may show discordance between histologic tumor grade or extent and clinical outcome. Data from The Cancer Genome Atlas (TCGA) demonstrate that molecular/genomic classification often provides useful information regarding risk stratification and response to therapy.9–22  Here, we review diagnostic features of uncommon and newly proposed endometrial carcinoma subtypes that may be challenging to recognize, as well as ancillary studies that may facilitate classification. More accurate and consistent diagnosis will help establish their biological relevance.

Endometrial mesonephric-like carcinoma (MLCa) is a rare, aggressive carcinoma that often shows unimpressive cytologic features and may be misdiagnosed as International Federation of Gynecology and Obstetrics (FIGO) grade 1 to 2 endometrioid carcinoma. Endometrial mesonephric-like endometrial carcinoma frequently recurs and metastasizes, often to lung, but occasionally to unusual sites including the liver, brain, and eye.23–27  The 5-year disease-specific survival for endometrial MLCa is 72%.24  A single-institution study26  of 23 endometrial MLCa cases reported median progression-free survival of 18.2 months (compared with 183 months for low-grade endometrioid carcinomas and 67.1 months for serous carcinomas) and median overall survival of 70.6 months (compared with 139.1 months for serous carcinomas). MLCa should be regarded as a high-grade tumor.23,24 

MLCa typically shows variable architecture, including tubular, ductal, papillary, sievelike, corded, spindled, and glomeruloid patterns (Figure 1, A and B). As with its namesake, MLCa may show eosinophilic colloidlike secretions within tubules (Figure 1, C and D).23–30  Cytologic atypia tends to be relatively mild, and monotonous oval vesicular nuclei reminiscent of papillary thyroid carcinoma may be seen (Figure 1, E).23–30  Features reminiscent of corded and hyalinized endometrioid carcinoma (CHEC) or ovarian low-grade serous carcinoma have been reported in MLCa.28,30  Because solid, spindled areas may be present within the spectrum of MLCa, McCluggage24  recommends reserving a diagnosis of mesonephric-like carcinosarcoma for cases with heterologous sarcomatous elements. Some cases of MLCa are associated with endometrial atypical hyperplasia, supporting Müllerian origin.24,31  Endometrial MLCa is not associated with mesonephric remnants.32 

Figure 1.

Morphologic and immunohistochemical features of mesonephric-like carcinoma (MLCa). Endometrial MLCa can show a variety of growth patterns, the most striking of which include glomeruloid structures and small, bland tubules (A and B). The neoplastic tubules sometimes contain variably prominent eosinophilic secretions (C and D), reminiscent of true mesonephric adenocarcinoma. MLCa can show vaguely papillary thyroid carcinoma–like nuclear features, including overlapping, chromatin clearing, and nuclear grooves (E). MLCa is commonly positive for TTF-1 by immunohistochemistry (F) (hematoxylin-eosin, original magnifications ×100 [A], ×40 [B], ×200 [C and D], and ×400 [E]; TTF-1 immunochemistry, original magnification ×100 [F]).

Figure 1.

Morphologic and immunohistochemical features of mesonephric-like carcinoma (MLCa). Endometrial MLCa can show a variety of growth patterns, the most striking of which include glomeruloid structures and small, bland tubules (A and B). The neoplastic tubules sometimes contain variably prominent eosinophilic secretions (C and D), reminiscent of true mesonephric adenocarcinoma. MLCa can show vaguely papillary thyroid carcinoma–like nuclear features, including overlapping, chromatin clearing, and nuclear grooves (E). MLCa is commonly positive for TTF-1 by immunohistochemistry (F) (hematoxylin-eosin, original magnifications ×100 [A], ×40 [B], ×200 [C and D], and ×400 [E]; TTF-1 immunochemistry, original magnification ×100 [F]).

Close modal

Immunohistochemical workup can facilitate accurate classification of these tumors. Expression of estrogen receptor (ER) and progesterone receptor (PR) should be absent or very limited; although some degree of ER staining is acceptable, PR staining is vanishingly rare.26,29,32,33  The neoplastic cells may be positive for GATA3, TTF-1 (Figure 1, F), and/or luminal CD10.24,25,28  TTF-1 and GATA3 tend to demonstrate an inverse staining pattern, and MLCa often shows diffuse staining for one of these markers.23,24,28  TTF-1 and ER are good as first-line screens, but not all TTF-1–positive/ER-negative endometrial carcinomas are mesonephric-like carcinomas.25  Immunohistochemical or molecular evidence of mismatch repair deficiency or microsatellite instability argues against a diagnosis of MLCa, as do areas of squamous or mucinous differentiation.24,25,28  MLCa should show nonaberrant staining for p53 protein.24,28  Napsin A and HNF1B staining have been negative in the cases reported in the literature.26,32 

MLCa often harbors KRAS mutations without mismatch repair deficiency, TP53 mutation, or PTEN mutation; however, KRAS mutations are also often seen in endometrioid carcinoma with mucinous differentiation.25,28,34 PIK3R1 mutation has been reported in MLCa but not in true mesonephric carcinoma.28  MLCa is thought to represent approximately 1% of all endometrial carcinomas and 5% of KRAS-mutated microsatellite-stable endometrial carcinomas.28  MLCa may show 1q amplification, but this is not a specific finding.28  Most MLCa cases fall into the copy number low/no specific molecular profile category in TCGA molecular classification of endometrial carcinomas.24  Two cases of KRAS-mutated endometrial MLCa with excellent and durable responses to lenvatinib and pembrolizumab have been reported,35  although further studies are needed.

Some cases of low-grade endometrial endometrioid carcinoma show significant morphologic overlap with endocervical microglandular hyperplasia (MGH).36–40  Because of the bland appearance of these endometrial carcinomas, misdiagnosis as MGH is not uncommon.36–38  Additionally, rare cases of MGH have atypical features, simulating carcinoma.39,40  Microglandular proliferations in samples from postmenopausal women are concerning, as even MGH is an abnormal finding in the absence of hormone therapy. MGH may be indicative of hormone excess,39,41  which warrants further sampling to exclude the possibility of concurrent hyperplasia or malignancy.

Classic features of MGH include proliferation of small, tightly packed glands lined by bland cuboidal or low columnar mucinous epithelium, often with subnuclear vacuoles, rare to absent mitotic figures, and abundant acute and chronic inflammation.39,42  Unusual features reported in so-called atypical MGH include signet ring cells, hobnail cells, nuclear atypia, mitotic figures, and solid, reticular, cribriform, or pseudoinfiltrative architecture.40,43 

Although MGH is often associated with reserve cell hyperplasia, luminal squamous metaplasia is seen more often in low-grade endometrioid carcinoma.42  Cytologic atypia, mitotic activity, foamy histiocytes (stromal foam cells), and medium to large complex glands are more common in endometrioid carcinoma (Figure 2, A and B).38,42,44,45  Rare mitotic figures can be seen in either entity.42,44,46  If a subcolumnar reserve cell layer can be identified in the microglandular proliferation, a diagnosis of MGH can be made.44  Small, tightly packed glands and subnuclear vacuoles are more common in MGH cases.38,44,45 

Figure 2.

Morphologic and immunohistochemical features of low-grade endometrioid carcinoma resembling endocervical microglandular hyperplasia. Although low-grade endometrioid carcinoma may show significant morphologic overlap with endocervical microglandular hyperplasia, the presence of medium to large crowded glands with mild cytologic atypia is more characteristic of endometrioid carcinoma (A and B). The presence of rare admixed endometrial-type glands may be helpful. Endocervical microglandular hyperplasia is characterized by small, tightly packed glands with mucinous and vacuolated features; the subcolumnar reserve cell layer is variably prominent on hematoxylin-eosin but can be highlighted with a p63 immunostain (C and D). Though endometrioid carcinoma may show small, tightly packed glands with associated neutrophils, p63 does not reveal a subcolumnar reserve cell layer (hematoxylin-eosin, original magnification ×200 [A through C and E]; p63 immunohistochemistry, original magnification ×200 [D and F]).

Figure 2.

Morphologic and immunohistochemical features of low-grade endometrioid carcinoma resembling endocervical microglandular hyperplasia. Although low-grade endometrioid carcinoma may show significant morphologic overlap with endocervical microglandular hyperplasia, the presence of medium to large crowded glands with mild cytologic atypia is more characteristic of endometrioid carcinoma (A and B). The presence of rare admixed endometrial-type glands may be helpful. Endocervical microglandular hyperplasia is characterized by small, tightly packed glands with mucinous and vacuolated features; the subcolumnar reserve cell layer is variably prominent on hematoxylin-eosin but can be highlighted with a p63 immunostain (C and D). Though endometrioid carcinoma may show small, tightly packed glands with associated neutrophils, p63 does not reveal a subcolumnar reserve cell layer (hematoxylin-eosin, original magnification ×200 [A through C and E]; p63 immunohistochemistry, original magnification ×200 [D and F]).

Close modal

The immunohistochemical stains typically used to assess for endometrial versus endocervical origin do not assist with this differential diagnosis. MGH is not associated with high-risk human papillomavirus; therefore, p16 assessment is not particularly helpful. MGH and low-grade endometrioid carcinomas may show overlapping results for ER, PR, vimentin, and Ki-67.42,43  Consistent p63-positive subcolumnar reserve cells46  are seen only in MGH (comparison shown in Figure 2, C through F), whereas loss of PTEN44  and/or PAX243  expression is much more commonly seen in endometrioid carcinoma.

KRAS mutation has been detected in a large subset of microglandular endometrioid carcinoma cases but has been absent in mitotically active MGH cases.47 

Polymerase epsilon (POLE) plays a role in proofreading and error correction during DNA replication.48  Mutations in the exonuclease domain of POLE lead to an ultramutated phenotype. POLE-ultramutated (POLEmut) endometrial carcinoma tends to be diagnosed at a younger age (median, 55 years), in patients with a lower body mass index, and at low stage.49,50  Although POLEmut endometrial carcinomas frequently show concerning histopathologic features, the clinical outcomes are excellent in retrospective studies (with close to 100% recurrence-free survival).15–17,51–57  Post hoc analysis of samples from the PORTEC-3 clinical trial did not show benefit of adding chemotherapy to radiation in patients with POLEmut endometrial carcinoma, implying that the favorable outcome was not attributable to chemotherapy.15 

Nevertheless, there are rare reports of adverse outcomes in POLEmut endometrial carcinomas. In one study of 23 patients with POLEmut endometrial carcinoma, 4 patients had recurrent disease and 1 had progressive disease after a median follow-up of 30 months.57  One patient initially diagnosed with stage I disease underwent adjuvant intravaginal radiation therapy and subsequently developed isolated brain lesions that responded to treatment (surgical resection and stereotactic radiation, then stereotactic radiation and pembrolizumab). The other patient with brain metastasis died 33 months after being diagnosed with stage IV disease and being treated with chemotherapy. A meta-analysis of data from 294 patients with POLEmut endometrial carcinoma has indicated high salvage rates in the rare recurrences of POLEmut ECs.57,58  In the recurrent or metastatic setting, POLEmut tumors may respond to immunotherapy.55,59–63  PORTEC-4a (Molecular Profile–Based Versus Standard Adjuvant Radiotherapy in Endometrial Cancer; https://classic.clinicaltrials.gov/ct2/show/NCT03469674) is randomizing patients between the standard treatment and molecular-integrated risk-based individualized treatment and will show if omitting treatment in cases of favorable molecular profiles is safe and cost-effective.

POLEmut endometrial carcinoma typically shows features of endometrioid carcinoma (often high-grade/FIGO grade 3; Figure 3, A and B), though POLEmut endometrial carcinomas with serous and clear cell histotypes have also been documented.58  Mixed differentiation, morphologic heterogeneity, and ambiguous histologic features are also commonly described.49,58  The nuclear grade and mitotic index are often high, and lymphovascular invasion is common.49,58  Peritumoral lymphocytes and tumor-infiltrating lymphocytes are typically present (Figure 3, C and D),49,58  and scattered bizarre cells and serouslike atypia are also characteristic of these tumors (Figure 3, E and F). Other unique morphologic patterns that have been reported include lymphoepithelioma-like.49  Although these features are enriched in POLEmut tumors, they can be seen across all 4 molecular groups, emphasizing the importance of molecular testing.22 

Figure 3.

Morphologic features of polymerase epsilonultramutated (POLEmut) endometrial carcinoma. POLEmut endometrial carcinoma often shows heterogeneous or ambiguous morphology, frequently with an endometrioid component (A and B). Peritumoral chronic inflammation and tumor-infiltrating lymphocytes are commonly seen (C and D). Areas of bizarre serouslike atypia may raise concern for the possibility of serous carcinoma but are known to occur in POLEmut endometrial carcinoma as well (E and F) (hematoxylin-eosin, original magnifications ×200 [A, B, E, and F], ×40 [C], and ×400 [D]).

Figure 3.

Morphologic features of polymerase epsilonultramutated (POLEmut) endometrial carcinoma. POLEmut endometrial carcinoma often shows heterogeneous or ambiguous morphology, frequently with an endometrioid component (A and B). Peritumoral chronic inflammation and tumor-infiltrating lymphocytes are commonly seen (C and D). Areas of bizarre serouslike atypia may raise concern for the possibility of serous carcinoma but are known to occur in POLEmut endometrial carcinoma as well (E and F) (hematoxylin-eosin, original magnifications ×200 [A, B, E, and F], ×40 [C], and ×400 [D]).

Close modal

The Proactive Molecular Risk Classifier for Endometrial Cancer separates ECs into the following 4 categories using a limited panel of tests (immunohistochemistry for mismatch repair proteins and p53 and testing for POLE exonuclease domain pathogenic variants): POLE mutated, mismatch repair deficient, p53 abnormal, and p53 wild type.16,19  For a tumor to be classified as POLEmut EC, the detected mutation should be within the exonuclease domain and should be recognized as a pathogenic mutation. The most common pathogenic POLE exonuclease domain mutations are P286R, V411L, S297F, A456P, and S459F.64  ECs with nonpathogenic POLE exonuclease domain mutations do not show the same excellent prognosis as those ECs with pathogenic POLE exonuclease domain mutations. Microsatellite instability–high (MSI-H) ECs with POLE mutation outside the exonuclease domain have similar genomic characteristics to MSI-H ECs without POLE mutation.64  No specific POLE mutations have been associated with disease recurrence.

POLEmut endometrial carcinoma may acquire additional mismatch repair–associated mutational signatures during clonal evolution. A subset of POLEmut tumors shows only focal abnormal p53 staining with an abrupt transition to nonaberrant/wild-type staining patterns.58  Of note, TP53 mutations have been reported in approximately one-third of POLEmut tumors.49  Some authors believe that the serouslike or ambiguous features in these tumors may result from somatic mutations occurring secondary to the POLE mutation.49,58  It has been postulated that this may also be the reason for heterogeneous patterns of staining for p53 and mismatch repair proteins.58  Double-classifier POLEmut-p53abn tumors and POLEmut MSI-H tumors behave like POLEmut tumors.64,65  Tumor molecular classification of early-stage high-risk EC using next-generation sequencing for POLE exonuclease domain mutation in combination with immunohistochemical assessment of p53 and mismatch repair proteins has been shown to be cost-effective based on a Markov decision model.66 

Among the less common appearances of endometrial endometrioid carcinoma is a biphasic pattern with spindling or cording of the epithelial cells, extensive hyalinization, and sometimes even osteoid formation, which may lead to misdiagnosis as carcinosarcoma.67  In 2005, Murray et al68  described a series of 31 cases of endometrioid adenocarcinoma with areas forming “cords, spindle cells, fusiform cells, or a striking hyalinized stroma,” invariably associated with a more typical villoglandular endometrioid carcinoma (often low-grade) comprising 10% to 90% of the tumor, which they termed CHEC. A total of 62 cases have been reported in the literature,69–73  although the pattern is assuredly more common than this number suggests.

Initially, CHECs were thought to have a good prognosis, as they are often associated with a low-grade endometrioid carcinoma, but a small subset of reported cases has displayed more aggressive behavior. There are 29 reported cases with follow-up data. While the majority of patients (78%) have shown no evidence of disease at last follow-up, approximately 8% of patients were alive with disease and approximately 8% of patients had died of disease at last follow-up.73  All patients who died of disease had a FIGO grade 2 endometrioid component and presented at stage II or higher. Poor outcomes in some cases are less surprising in light of reports that EC with CTNNB1 alterations, common in CHEC, portends a worse prognosis.74,75 

These tumors most often show anastomosing cords of tumor cells within a variably dense hyalinized background (Figure 4, A). In some cases, the hyalinization may be minimal, resulting in a sex cord–like appearance (Figure 4, B). A spindle cell component may be present, either along with the corded component or in lieu of it (Figure 4, A and C). Myxoid, osteoid, and chondroid stroma may be present.73,76  The CHEC pattern is often a minor component of the tumor, with the remainder composed of gland-forming endometrioid carcinoma, usually FIGO grade 1 or 2 (45 of 47 cases; 96%). In rare cases, a higher-grade endometrioid carcinoma may be present (Figure 4, D). That said, the corded and hyalinized component is often localized to the superficial aspect of the tumor and therefore may be disproportionately represented on endometrial biopsies and curettings.73  A squamous component (frequently abrupt and keratinizing) is present in the majority of cases, and lymphovascular space invasion is not uncommon, seen in approximately one-quarter of cases.70,73  The current recommendation is to grade CHEC based on the architecture of the conventional glandular component.76 

Figure 4.

Morphologic features of corded and hyalinized endometrioid carcinoma (CHEC). CHEC can show variable morphology, including cords of cells (B), spindle cells (C), or a combination of both (A). Although most are associated with low-grade endometrioid carcinoma, a subset is associated with high-grade carcinoma (D). These tumors are usually positive for β-catenin (E) but negative for hormone receptors (F) (hematoxylin-eosin, original magnification ×100 [A through D]; β-catenin, original magnification ×100 [E]; estrogen receptor, original magnification ×100 [F]).

Figure 4.

Morphologic features of corded and hyalinized endometrioid carcinoma (CHEC). CHEC can show variable morphology, including cords of cells (B), spindle cells (C), or a combination of both (A). Although most are associated with low-grade endometrioid carcinoma, a subset is associated with high-grade carcinoma (D). These tumors are usually positive for β-catenin (E) but negative for hormone receptors (F) (hematoxylin-eosin, original magnification ×100 [A through D]; β-catenin, original magnification ×100 [E]; estrogen receptor, original magnification ×100 [F]).

Close modal

Immunohistochemically, the corded and hyalinized areas often show less extensive cytokeratin expression and more vimentin expression than the typical endometrioid component. The corded and hyalinized areas typically show nuclear positivity for β-catenin (Figure 4, E), and the glandular areas can also show at least focal nuclear staining. Expression of hormone receptors (ER, PR) is variable, but the corded component often shows lower expression than the glandular component and may be negative or only focally positive (Figure 4, F).

The majority of CHECs demonstrate alterations in the CTNNB1 gene, as suggested by their nuclear β-catenin staining. Unsurprisingly, most CHECs fall into the no specific molecular profile TCGA category. Cases with high-grade features (cytologic atypia, brisk mitotic activity) in the corded and hyalinized component (high-grade CHEC) may show TP53 and RB1 alterations in addition to CTNNB1 and PI3K pathway mutations,70  and Safdar et al71  described 1 case with low-grade endometrioid carcinoma and low-grade CHEC components showing strong and diffuse p53 staining in both components. A study of 6 cases reported as CHEC with high-grade morphologic features in the corded and hyalinized component demonstrated mismatch repair deficiency in 3 (2 of which had high-grade endometrioid components) and aberrant overexpression of p53 in 2 (both with high-grade endometrioid components).72  To our knowledge, there have been no reported ultramutated CHECs. Further studies are required to clarify the appropriate classification of tumors with high-grade corded and hyalinized and/or glandular components.

Unlike endometrial endometrioid carcinoma, which is often associated with endometrial atypical hyperplasia/endometrioid intraepithelial neoplasia, uterine serous carcinoma (USC) does not have a well-defined precursor lesion. As in the fallopian tube, p53 signatures—stretches of endometrial glandular epithelium with aberrant p53 staining—have been identified in association with USC and even show identical TP53 alterations.77,78  Endometrial glandular dysplasia, a morphologically atypical lesion within the endometrium that falls short of serous carcinoma but harbors similar molecular findings,79,80  is considered by some to represent a premalignant serous lesion.81,82  However, unlike endometrial atypical hyperplasia/endometrioid intraepithelial neoplasia, these diagnoses may not be reproducible in the absence of coexisting serous carcinoma.

Serous endometrial intraepithelial carcinoma (SEIC) was originally described as a finding seen adjacent to carcinoma in up to 90% of cases of USC and was thought to represent a precursor lesion and/or intraepithelial spread.83–86  Soon after, Zheng et al86  suggested the term uterine surface carcinoma instead of endometrial intraepithelial carcinoma to emphasize the “unique aggressive nature” of SEIC and its potential for metastasis. Nonmyoinvasive USC was already established to have the potential for spread, with lymph node metastasis in 36% of cases and intraperitoneal disease in 43% in a broad study of USC by Goff et al,87  and 3 bona fide cases of SEIC with extrauterine disease in the absence of USC were later reported as well.88 Minimal USC (MUSC) was proposed by Wheeler and colleagues89  as an umbrella term for USC that was nonmyoinvasive and measured 1 cm or less in greatest extent.

MUSC is, as the name suggests, a serous carcinoma—morphologically, immunophenotypically, and molecularly indistinguishable from the more invasive USC. The tumor is small but otherwise meets cytologic criteria for serous carcinoma, with enlarged epithelial cells having eosinophilic cytoplasm, variably sized nuclei, prominent nucleoli, and frequent mitotic activity. They almost invariably harbor TP53 alterations with aberrant expression of p53 by immunohistochemistry.

There is a close association between MUSC and endometrial polyps, with 80% to 90% of cases involving a polyp and around half (48%–53%) confined to one.89–91  Compared with patients whose MUSC extends from a polyp to the background endometrium, patients with polyp-confined disease are much less likely to have extrauterine spread at the time of staging resection (17% versus 41.7% in non–polyp-confined cases) or to die of disease (9.4% versus 29.2%).92 

The subtle presentation of MUSC belies its potential for high-stage disease. Between 33% and 45% of patients with MUSC have extrauterine disease at presentation, most commonly peritoneal spread but occasionally lymph node metastasis,89,90  and therefore patients with any serous carcinoma on endometrial sampling or polypectomy, even SEIC, should undergo a full staging resection. For this reason, the 5th edition of the World Health Organization classification of female genital tumors discusses SEIC in the “serous carcinoma of the uterine corpus” section rather than listing it as a distinct diagnostic entity.93  Endometrial polyps should be entirely submitted for histologic evaluation, as should the endometrium in a hysterectomy for endometrial serous carcinoma without a grossly identifiable lesion. Fortunately, noninvasive USC, including MUSC, that is limited to the uterus has a good prognosis, with a 5-year survival rate of around 90%.94  Spread beyond the uterus dampens the prognosis considerably.

Evaluation for HER2 overexpression may be a reasonable consideration even in early-stage disease, as HER2 positivity has been shown to predict for lymphovascular invasion and recurrence.95  Trastuzumab added to conventional chemotherapy improves progression-free survival in patients with advanced-stage or recurrent HER2-positive USC.96  Neratinib, alone or in combination with olaparib, has shown promise in HER2-positive USC cell lines as well.97 

As described above, there are multiple situations in which accurate classification of endometrial carcinomas can be challenging, and awareness of pitfalls and immunohistochemical or molecular tests are of critical importance. Variants of endometrioid carcinoma may show morphologic similarity to benign endocervical MGH or carcinosarcoma. Aggressive carcinoma subtypes such as mesonephric-like endometrial carcinoma can have a low-grade histologic appearance, whereas POLEmut carcinomas (with expected favorable clinical course) often have a high-grade appearance. Even carcinomas that are limited in extent, such as MUSC, can have a poor prognosis. Recognition of these cancer subtypes allows for more accurate prognostication and can guide clinicians’ approach to treatment.

1.
Miller
KD,
Nogueira
L,
Devasia
T,
et al.
Cancer treatment and survivorship statistics, 2022
.
CA Cancer J Clin
.
2022
;
72
(
5
):
409
436
.
2.
Murali
R,
Davidson
B,
Fadare
O,
et al.
High-grade endometrial carcinomas: morphologic and immunohistochemical features, diagnostic challenges and recommendations
.
Int J Gynecol Pathol
.
2019
;
38
(1)(suppl 1
):
S40
S63
.
3.
Gilks
CB,
Oliva
E,
Soslow
RA.
Poor interobserver reproducibility in the diagnosis of high-grade endometrial carcinoma
.
Am J Surg Pathol
.
2013
;
37
(
6
):
874
881
.
4.
Han
G,
Sidhu
D,
Duggan
MA,
et al.
Reproducibility of histological cell type in high-grade endometrial carcinoma
.
Mod Pathol
.
2013
;
26
(
12
):
1594
1604
.
5.
Fadare
O,
Parkash
V,
Dupont
WD,
et al.
The diagnosis of endometrial carcinomas with clear cells by gynecologic pathologists: an assessment of interobserver variability and associated morphologic features
.
Am J Surg Pathol
.
2012
;
36
(
8
):
1107
1118
.
6.
Colombo
N,
Creutzberg
C,
Amant
F,
et al.
ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up
.
Ann Oncol
.
2016
;
27
(
1
):
16
41
.
7.
Creasman
WT,
Odicino
F,
Maisonneuve
P,
et al.
Carcinoma of the corpus uteri: FIGO 26th annual report on the results of treatment in gynecological cancer
.
Int J Gynaecol Obstet
.
2006
;
95
(
suppl 1
):
S105
S143
.
8.
Kong
A,
Johnson
N,
Kitchener
HC,
Lawrie
TA.
Adjuvant radiotherapy for stage I endometrial cancer: an updated Cochrane systematic review and meta-analysis
.
J Natl Cancer Inst
.
2012
;
104
(
21
):
1625
1634
.
9.
Kandoth
C,
Schultz
N,
Cherniack
AD,
et al.
Integrated genomic characterization of endometrial carcinoma
.
Nature
.
2013
;
497
(
7447
):
67
73
.
10.
Talhouk
A,
McConechy
MK,
Leung
S,
et al.
A clinically applicable molecular-based classification for endometrial cancers
.
Br J Cancer
.
2015
;
113
(
2
):
299
310
.
11.
Talhouk
A,
Hoang
LN,
McConechy
MK,
et al.
Molecular classification of endometrial carcinoma on diagnostic specimens is highly concordant with final hysterectomy: earlier prognostic information to guide treatment
.
Gynecol Oncol
.
2016
;
143
(
1
):
46
53
.
12.
Kommoss
S,
McConechy
MK,
Kommoss
F,
et al.
Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series
.
Ann Oncol
.
2018
;
29
(
5
):
1180
1188
.
13.
Stelloo
E,
Nout
RA,
Osse
EM,
et al.
Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer—combined analysis of the PORTEC cohorts
.
Clin Cancer Res
.
2016
;
22
(
16
):
4215
4224
.
14.
Vermij
L,
Smit
V,
Nout
R,
Bosse
T.
Incorporation of molecular characteristics into endometrial cancer management
.
Histopathology
.
2020
;
76
(
1
):
52
63
.
15.
León-Castillo
A,
de Boer
SM,
Powell
ME,
et al.
Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy
.
J Clin Oncol
.
2020
;
38
(
29
):
3388
3397
.
16.
Talhouk
A,
McConechy
MK,
Leung
S,
et al.
Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer
.
Cancer
.
2017
;
123
(
5
):
802
813
.
17.
Stelloo
E,
Bosse
T,
Nout
RA,
et al.
Refining prognosis and identifying targetable pathways for high-risk endometrial cancer: a TransPORTEC initiative
.
Mod Pathol
.
2015
;
28
(
6
):
836
844
.
18.
Bosse
T,
Nout
RA,
McAlpine
JN,
et al.
Molecular classification of grade 3 endometrioid endometrial cancers identifies distinct prognostic subgroups
.
Am J Surg Pathol
.
2018
;
42
(
5
):
561
568
.
19.
Casey
L,
Singh
N.
POLE, MMR, and MSI testing in endometrial cancer: proceedings of the ISGyP Companion Society Session at the USCAP 2020 annual meeting
.
Int J Gynecol Pathol
.
2021
;
40
(
1
):
5
16
.
20.
Jamieson
A,
Huvila
J,
Thompson
EF,
et al.
Variation in practice in endometrial cancer and potential for improved care and equity through molecular classification
.
Gynecol Oncol
.
2022
;
165
(
2
):
201
214
.
21.
Hoang
LN,
Kinloch
MA,
Leo
JM,
et al.
Interobserver agreement in endometrial carcinoma histotype diagnosis varies depending on the Cancer Genome Atlas (TCGA)-based molecular subgroup
.
Am J Surg Pathol
.
2017
;
41
(
2
):
245
252
.
22.
Joehlin-Price
A,
Van Ziffle
J,
Hills
NK,
Ladwig
N,
Rabban
JT,
Garg
K.
Molecularly classified uterine FIGO grade 3 endometrioid carcinomas show distinctive clinical outcomes but overlapping morphologic features
.
Am J Surg Pathol
.
2021
;
45
(
3
):
421
429
.
23.
Pors
J,
Segura
S,
Chiu
DS,
et al.
Clinicopathologic characteristics of mesonephric adenocarcinomas and mesonephric-like adenocarcinomas in the gynecologic tract: a multi-institutional study
.
Am J Surg Pathol
.
2021
;
45
(
4
):
498
506
.
24.
McCluggage
WG.
Mesonephric-like adenocarcinoma of the female genital tract: from morphologic observations to a well-characterized carcinoma with aggressive clinical behavior
.
Adv Anat Pathol
.
2022
;
29
(
4
):
208
216
.
25.
Mills
AM,
Jenkins
TM,
Howitt
BE,
Fan
J,
Ring
KL,
Cook
I.
Mesonephric-like endometrial carcinoma: results from immunohistochemical screening of 300 endometrial carcinomas and carcinosarcomas for this often overlooked and potentially aggressive entity
.
Am J Surg Pathol
.
2022
;
46
(
7
):
921
932
.
26.
Euscher
ED,
Bassett
R,
Duose
DY,
et al.
Mesonephric-like carcinoma of the endometrium: a subset of endometrial carcinoma with an aggressive behavior
.
Am J Surg Pathol
.
2020
;
44
(
4
):
429
443
.
27.
Al Nabhani
S,
Doyle
A,
Kennedy
S,
McVey
R,
Crown
J,
Gibbons
D.
Endometrial mesonephric-like adenocarcinoma presenting as an ocular lesion: a case report
.
Int J Gynecol Pathol
.
2022
;
41
(
2
):
161
167
.
28.
Kolin
DL,
Costigan
DC,
Dong
F,
Nucci
MR,
Howitt
BE.
A combined morphologic and molecular approach to retrospectively identify KRAS-mutated mesonephric-like adenocarcinomas of the endometrium
.
Am J Surg Pathol
.
2019
;
43
(
3
):
389
398
.
29.
Mirkovic
J.
Uncommon and difficult high-grade endometrial carcinomas
.
Surg Pathol Clin
.
2022
;
15
(
2
):
301
314
.
30.
Patel
V,
Kipp
B,
Schoolmeester
JK.
Corded and hyalinized mesonephric-like adenocarcinoma of the uterine corpus: report of a case mimicking endometrioid carcinoma
.
Hum Pathol
.
2019
;
86
:
243
248
.
31.
da Silva
EM,
Fix
DJ,
Sebastiao
APM,
et al.
Mesonephric and mesonephric-like carcinomas of the female genital tract: molecular characterization including cases with mixed histology and matched metastases
.
Mod Pathol
.
2021
;
34
(
8
):
1570
1587
.
32.
McFarland
M,
Quick
CM,
McCluggage
WG.
Hormone receptor-negative, thyroid transcription factor 1-positive uterine and ovarian adenocarcinomas: report of a series of mesonephric-like adenocarcinomas
.
Histopathology
.
2016
;
68
(
7
):
1013
1020
.
33.
Na
K,
Kim
HS.
Clinicopathologic and molecular characteristics of mesonephric adenocarcinoma arising from the uterine body
.
Am J Surg Pathol
.
2019
;
43
(
1
):
12
25
.
34.
Mirkovic
J,
McFarland
M,
Garcia
E,
et al.
Targeted genomic profiling reveals recurrent KRAS mutations in mesonephric-like adenocarcinomas of the female genital tract
.
Am J Surg Pathol
.
2018
;
42
(
2
):
227
233
.
35.
Shen
S,
Rubinstein
MM,
Park
KJ,
Konner
JA,
Makker
V.
Sustained response to lenvatinib and pembrolizumab in two patients with KRAS-mutated endometrial mesonephric-like adenocarcinoma
.
Gynecol Oncol Rep
.
2021
;
37
:
100844
.
36.
McCluggage
WG,
Perenyei
M.
Microglandular adenocarcinoma of the endometrium
.
Histopathology
.
2000
;
37
(
3
):
285
287
.
37.
Young
RH,
Scully
RE.
Uterine carcinomas simulating microglandular hyperplasia: a report of six cases
.
Am J Surg Pathol
.
1992
;
16
(
11
):
1092
1097
.
38.
Zaloudek
C,
Hayashi
GM,
Ryan
IP,
Powell
CB,
Miller
TR.
Microglandular adenocarcinoma of the endometrium: a form of mucinous adenocarcinoma that may be confused with microglandular hyperplasia of the cervix
.
Int J Gynecol Pathol
.
1997
;
16
(
1
):
52
59
.
39.
Young
RH,
Clement
PB.
Pseudoneoplastic glandular lesions of the uterine cervix
.
Semin Diagn Pathol
.
1991
;
8
(
4
):
234
249
.
40.
Young
RH,
Scully
RE.
Atypical forms of microglandular hyperplasia of the cervix simulating carcinoma: a report of five cases and review of the literature
.
Am J Surg Pathol
.
1989
;
13
(
1
):
50
56
.
41.
Taylor
HB,
Irey
NS,
Norris
HJ.
Atypical endocervical hyperplasia in women taking oral contraceptives
.
JAMA
.
1967
;
202
(
7
):
637
639
.
42.
Qiu
W,
Mittal
K.
Comparison of morphologic and immunohistochemical features of cervical microglandular hyperplasia with low-grade mucinous adenocarcinoma of the endometrium
.
Int J Gynecol Pathol
.
2003
;
22
(
3
):
261
265
.
43.
Stewart
CJ,
Crook
ML.
PAX2 and cyclin D1 expression in the distinction between cervical microglandular hyperplasia and endometrial microglandular-like carcinoma: a comparison with p16, vimentin, and Ki67
.
Int J Gynecol Pathol
.
2015
;
34
(
1
):
90
100
.
44.
Aoun
BA,
Skala
SL.
Utility of p63 and PTEN staining in distinguishing cervical microglandular hyperplasia from endometrial endometrioid carcinoma with microglandular/mucinous features
.
Histopathology
.
2022
;
80
(
7
):
1102
1111
.
45.
Pavlakis
K,
Vrekoussis
T,
Messini
I,
et al.
Mucinous epithelial lesions in endometrial curettage material: a diagnostic challenge
.
Appl Immunohistochem Mol Morphol
.
2012
;
20
(
6
):
607
613
.
46.
Houghton
O,
McCluggage
WG.
The expression and diagnostic utility of p63 in the female genital tract
.
Adv Anat Pathol
.
2009
;
16
(
5
):
316
321
.
47.
Hong
W,
Abi-Raad
R,
Alomari
AK,
Hui
P,
Buza
N.
Diagnostic application of KRAS mutation testing in uterine microglandular proliferations
.
Hum Pathol
.
2015
;
46
(
7
):
1000
1005
.
48.
Rayner
E,
van Gool
IC,
Palles
C,
et al.
A panoply of errors: polymerase proofreading domain mutations in cancer
.
Nat Rev Cancer
.
2016
;
16
(
2
):
71
81
.
49.
Hussein
YR,
Weigelt
B,
Levine
DA,
et al.
Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations
.
Mod Pathol
.
2015
;
28
(
4
):
505
514
.
50.
Raffone
A,
Travaglino
A,
Gabrielli
O,
et al.
Clinical features of ProMisE groups identify different phenotypes of patients with endometrial cancer
.
Arch Gynecol Obstet
.
2021
;
303
(
6
):
1393
1400
.
51.
Meng
B,
Hoang
LN,
McIntyre
JB,
et al.
POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium
.
Gynecol Oncol
.
2014
;
134
(
1
):
15
19
.
52.
McConechy
MK,
Talhouk
A,
Leung
S,
et al.
Endometrial carcinomas with POLE exonuclease domain mutations have a favorable prognosis
.
Clin Cancer Res
.
2016
;
22
(
12
):
2865
2873
.
53.
Leon-Castillo
A,
Horeweg
N,
Peters
EEM,
et al.
Prognostic relevance of the molecular classification in high-grade endometrial cancer for patients staged by lymphadenectomy and without adjuvant treatment
.
Gynecol Oncol
.
2022
;
164
(
3
):
577
586
.
54.
Britton
H,
Huang
L,
Lum
A,
et al.
Molecular classification defines outcomes and opportunities in young women with endometrial carcinoma
.
Gynecol Oncol
.
2019
;
153
(
3
):
487
495
.
55.
Bellone
S,
Bignotti
E,
Lonardi
S,
et al.
Polymerase ε (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro
.
Gynecol Oncol
.
2017
;
144
(
1
):
146
152
.
56.
Bakhsh
S,
Kinloch
M,
Hoang
LN,
et al.
Histopathological features of endometrial carcinomas associated with POLE mutations: implications for decisions about adjuvant therapy
.
Histopathology
.
2016
;
68
(
6
):
916
924
.
57.
Stasenko
M,
Tunnage
I,
Ashley
CW,
et al.
Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer
.
Gynecol Oncol
.
2020
;
156
(
1
):
194
202
.
58.
McAlpine
JN,
Chiu
DS,
Nout
RA,
et al.
Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: an individual patient data meta-analysis
.
Cancer
.
2021
;
127
(
14
):
2409
2422
.
59.
Pasanen
A,
Ahvenainen
T,
Pellinen
T,
Vahteristo
P,
Loukovaara
M,
Bützow
R.
PD-L1 expression in endometrial carcinoma cells and intratumoral immune cells: differences across histologic and TCGA-based molecular subgroups
.
Am J Surg Pathol
.
2020
;
44
(
2
):
174
181
.
60.
Howitt
BE,
Shukla
SA,
Sholl
LM,
et al.
Association of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1
.
JAMA Oncol
.
2015
;
1
(
9
):
1319
1323
.
61.
Gargiulo
P,
Della Pepa
C,
Berardi
S,
et al.
Tumor genotype and immune microenvironment in POLE-ultramutated and MSI-hypermutated endometrial cancers: new candidates for checkpoint blockade immunotherapy
?
Cancer Treat Rev
.
2016
;
48
:
61
68
.
62.
Gadducci
A,
Guerrieri
ME.
Immune checkpoint inhibitors in gynecological cancers: update of literature and perspectives of clinical research
.
Anticancer Res
.
2017
;
37
(
11
):
5955
5965
.
63.
Veneris
JT,
Lee
EK,
Goebel
EA,
et al.
Diagnosis and management of a recurrent polymerase-epsilon (POLE)-mutated endometrial cancer
.
Gynecol Oncol
.
2019
;
153
(
3
):
471
478
.
64.
León-Castillo
A,
Britton
H,
McConechy
MK,
et al.
Interpretation of somatic POLE mutations in endometrial carcinoma
.
J Pathol
.
2020
;
250
(
3
):
323
335
.
65.
León-Castillo
A,
Gilvazquez
E,
Nout
R,
et al.
Clinicopathological and molecular characterisation of “multiple-classifier” endometrial carcinomas
.
J Pathol
.
2020
;
250
(
3
):
312
322
.
66.
Orellana
TJ,
Kim
H,
Beriwal
S,
et al.
Cost-effectiveness analysis of tumor molecular classification in high-risk early-stage endometrial cancer
.
Gynecol Oncol
.
2022
;
164
(
1
):
129
135
.
67.
Clement
PB,
Young
RH.
Endometrioid carcinoma of the uterine corpus: a review of its pathology with emphasis on recent advances and problematic aspects
.
Adv Anat Pathol
.
2002
;
9
(
3
):
145
184
.
68.
Murray
SK,
Clement
PB,
Young
RH.
Endometrioid carcinomas of the uterine corpus with sex cord-like formations, hyalinization, and other unusual morphologic features: a report of 31 cases of a neoplasm that may be confused with carcinosarcoma and other uterine neoplasms
.
Am J Surg Pathol
.
2005
;
29
(
2
):
157
166
.
69.
Wani
Y,
Saegusa
M,
Notohara
K.
Aberrant nuclear beta-catenin expression in the spindle or corded cells in so-called corded and hyalinized endometrioid carcinomas: another critical role of the unique morphological feature
.
Histol Histopathol
.
2009
;
24
(
2
):
149
155
.
[PubMed]
70.
Ladwig
NR,
Umetsu
SE,
Zaloudek
C,
Rabban
J,
Garg
K.
Corded and hyalinized endometrioid adenocarcinoma (CHEC) of the uterine corpus are characterized by CTNNB1 mutations and can show adverse clinical outcomes
.
Int J Gynecol Pathol
.
2021
;
40
(
2
):
103
115
.
71.
Safdar
NS,
Thompson
EF,
Gilks
CB,
et al.
Corded and hyalinized and spindled endometrioid endometrial carcinoma: a clinicopathologic and molecular analysis of 9 tumors based on the TCGA classifier
.
Am J Surg Pathol
.
2021
;
45
(
8
):
1038
1046
.
72.
Travaglino
A,
Arciuolo
D,
Santoro
A,
et al.
Corded and hyalinized endometrioid endometrial carcinoma with high-grade features: a clinicopathological and TCGA-based molecular analysis
.
Virchows Arch
.
2023
;
482
(
4
):
671
678
.
73.
Travaglino
A,
Arciuolo
D,
Santoro
A,
et al.
Corded and hyalinized endometrioid carcinoma: summary of clinical, histological, immunohistochemical and molecular data
.
Pathol Res Pract
.
2023
;
247: 247
:
154515
.
74.
Liu
Y,
Patel
L,
Mills
GB,
et al.
Clinical significance of CTNNB1 mutation and Wnt pathway activation in endometrioid endometrial carcinoma
.
J Natl Cancer Inst
.
2014
;
106
(
9
):
dju245
.
75.
Travaglino
A,
Raffone
A,
Raimondo
D,
et al.
Prognostic significance of CTNNB1 mutation in early stage endometrial carcinoma: a systematic review and meta-analysis
.
Arch Gynecol Obstet
.
2022
;
306
(
2
):
423
431
.
76.
Rabban
JT,
Gilks
CB,
Malpica
A,
et al.
Issues in the differential diagnosis of uterine low-grade endometrioid carcinoma, including mixed endometrial carcinomas: recommendations from the International Society of Gynecological Pathologists
.
Int J Gynecol Pathol
.
2019
;
38
:
1(suppl 1
):
S25
S39
.
77.
Jarboe
EA,
Pizer
ES,
Miron
A,
Monte
N,
Mutter
GL,
Crum
CP.
Evidence for a latent precursor (p53 signature) that may precede serous endometrial intraepithelial carcinoma
.
Mod Pathol
.
2009
;
22
(
3
):
345
350
.
78.
Zhang
X,
Liang
SX,
Jia
L,
et al.
Molecular identification of “latent precancers” for endometrial serous carcinoma in benign-appearing endometrium
.
Am J Pathol
.
2009
;
174
(
6
):
2000
2006
.
79.
Zheng
W,
Liang
SX,
Yu
H,
Rutherford
T,
Chambers
SK,
Schwartz
PE.
Endometrial glandular dysplasia: a newly defined precursor lesion of uterine papillary serous carcinoma, part I: morphologic features
.
Int J Surg Pathol
.
2004
;
12
(
3
):
207
223
.
80.
Liang
SX,
Chambers
SK,
Cheng
L,
Zhang
S,
Zhou
Y,
Zheng
W.
Endometrial glandular dysplasia: a putative precursor lesion of uterine papillary serous carcinoma, part II: molecular features
.
Int J Surg Pathol
.
2004
;
12
(
4
):
319
331
.
81.
Fadare
O,
Zheng
W.
Endometrial glandular dysplasia (EmGD): morphologically and biologically distinctive putative precursor lesions of type II endometrial cancers
.
Diagn Pathol
.
2008
;
3
:
6
.
82.
Zheng
W,
Xiang
L,
Fadare
O,
Kong
B.
A proposed model for endometrial serous carcinogenesis
.
Am J Surg Pathol
.
2011
;
35
(
1
):
e1
e14
.
83.
Ambros
RA,
Sherman
ME,
Zahn
CM,
Bitterman
P,
Kurman
RJ.
Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumors displaying serous differentiation
.
Hum Pathol
.
1995
;
26
(
11
):
1260
1267
.
84.
Sherman
ME,
Bur
ME,
Kurman
RJ.
p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis
.
Hum Pathol
.
1995
;
26
(
11
):
1268
1274
.
85.
Tashiro
H,
Isacson
C,
Levine
R,
Kurman
RJ,
Cho
KR,
Hedrick
L.
p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis
.
Am J Pathol
.
1997
;
150
(
1
):
177
185
.
86.
Zheng
W,
Khurana
R,
Farahmand
S,
Wang
Y,
Zhang
ZF,
Felix
JC.
p53 immunostaining as a significant adjunct diagnostic method for uterine surface carcinoma: precursor of uterine papillary serous carcinoma
.
Am J Surg Pathol
.
1998
;
22
(
12
):
1463
1473
.
87.
Goff
BA,
Kato
D,
Schmidt
RA,
et al.
Uterine papillary serous carcinoma: patterns of metastatic spread
.
Gynecol Oncol
.
1994
;
54
(
3
):
264
268
.
88.
Soslow
RA,
Pirog
E,
Isacson
C.
Endometrial intraepithelial carcinoma with associated peritoneal carcinomatosis
.
Am J Surg Pathol
.
2000
;
24
(
5
):
726
732
.
89.
Wheeler
DT,
Bell
KA,
Kurman
RJ,
Sherman
ME.
Minimal uterine serous carcinoma: diagnosis and clinicopathologic correlation
.
Am J Surg Pathol
.
2000
;
24
(
6
):
797
806
.
90.
Hui
P,
Kelly
M,
O’Malley
DM,
Tavassoli
F,
Schwartz
PE.
Minimal uterine serous carcinoma: a clinicopathological study of 40 cases
.
Mod Pathol
.
2005
;
18
(
1
):
75
82
.
91.
Pathiraja
P,
Dhar
S,
Haldar
K.
Serous endometrial intraepithelial carcinoma: a case series and literature review
.
Cancer Manag Res
.
2013
;
5
:
117
122
.
92.
Assem
H,
Rottmann
D,
Finkelstein
A,
et al.
Minimal uterine serous carcinoma and endometrial polyp: a close clinicopathological relationship
.
Hum Pathol
.
2021
;
118
:
1
8
.
93.
WHO Classification of Tumours Editorial Board
.
Female Genital Tumours
. 5th ed.
Lyon, France
:
International Agency for Research on Cancer
;
2020
. WHO Classification of Tumours; vol
4
.
94.
Ferriss
JS,
Erickson
BK,
Shih
IM,
Fader
AN.
Uterine serous carcinoma: key advances and novel treatment approaches
.
Int J Gynecol Cancer
.
2021
;
31
(
8
):
1165
1174
.
95.
Erickson
BK,
Najjar
O,
Damast
S,
et al.
Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: a multi-institutional cohort study
.
Gynecol Oncol
.
2020
;
159
(
1
):
17
22
.
96.
Fader
AN,
Roque
DM,
Siegel
E,
et al.
Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2/neu
.
J Clin Oncol
.
2018
;
36
(
20
):
2044
2051
.
97.
Yadav
G,
Roque
DM,
Bellone
S,
et al.
Synergistic activity of neratinib in combination with olaparib in uterine serous carcinoma overexpressing HER2/neu
.
Gynecol Oncol
.
2022
;
166
(
2
):
351
357
.

Author notes

Presented at the New Frontiers in Pathology Conference; October 26–28, 2022; Ann Arbor, Michigan.

Competing Interests

The authors have no relevant financial interest in the products or companies described in this article.